Phase i study of the poly(ADP-Ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7917-7923

  Plummer, Ruth ^a   Jones, Christopher ^a   Middleton, Mark ^b   Wilson, Richard ^d   Evans, Jeffrey ^e   Olsen, Anna ^c   Curtin, Nicola ^a   Boddy, Alan ^a   McHugh, Peter ^e   Newell, David ^a   Harris, Adrian ^b   Johnson, Patrick ^d   Steinfeldt, Heidi ^f   Dewji, Raz ^g   Wang, Diane ^f   Robson, Lesley ^h   Calvert, Hilary ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Department of Medical Oncology ^*  (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f PFIZER INC   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^h IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AG 014699; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOCHROME P450 2D6; DACARBAZINE; DRUG DERIVATIVE; INDOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLEAR CELL SARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SINGLE STRANDED DNA BREAK; SOLID TUMOR; THROMBOCYTOPENIA; COMET ASSAY; DNA STRAND BREAKAGE; DRUG EFFECT; GENETICS; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMET ASSAY; CYTOCHROME P-450 CYP2D6; DACARBAZINE; DNA BREAKS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS;

EID: 59449085305     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1223     Document Type: Article

References (46)

1. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:360-74.
2. Heinen CD,Schmutte C,Fishel R. DNA repair and tu-morigenesis:lessons from hereditary cancer syndromes. Cancer Biol Ther 2002;1:477-85.
3. Risinger MA, Groden J. Crosslinks and crosstalk:human cancer syndromes and DNA repair defects. Cancer Cell 2004;6:539-45.
4. Gatti L, Zunino F. Overview of tumor cell chemore-sistance mechanisms. Methods Mol Med 2005;111:127-48.
5. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 2005;31:603-17.
6. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly-(ADP-ribose) polymerase. Nature 2005;434:913-7.
7. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNArepair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
8. Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 2004;38:445-76.
9. de Murcia G, Menissier de Murcia J. Poly(ADP-ribose) polymerase:a molecular nick-sensor. Trends Biochem Sci 1994;19:172-6.
10. Calabrese CR, Almassy R, Barton S, et al. Antican-cer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
11. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol CancerTher 2003;2:371-82.
12. Tentori L, Leonetti C, Scarsella M, et al. Systemicad-ministration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, gli-oma, lymphoma. Clin Cancer Res 2003;9:5370-9.
13. Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005;7:1-20.
14. Sheridan C. Genentech raises stakes on PARP inhibitors. Nat Biotechnol 2006;24:1179-80.
15. Thomas HD, Calabrese CR, Batey MA, et al. Preclin-ical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6:945-56.
16. Danson SJ, Middleton MR. Temozolomide:a novel oral alkylating agent. Expert Rev Anticancer Ther 2001;1:13-9.
17. 6-methylguanine. Mutagenesis 2002;17:483-7.
18. 6-alkylguanine-DNAalkyl-transferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-7.
19. D'Atri S,Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998;54:334-41.
20. Beneke S, Diefenbach J, Burkle A. Poly(ADP-ribo-syl)ation inhibitors:promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer 2004;111:813-8.
21. Szabo C. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders:future directions. CurrVasc Pharmacol 2005;3:301-3.
22. Graziani G, Battaini F, Zhang J. PARP-1 inhibition to treat cancer, ischemia, inflammation. Pharmacol Res 2005;52:1-4.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al.;European Organization for Research and Treatment of Can-cer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
24. Plummer ER, Middleton MR, Jones C, et al. Temo-zolomide pharmacodynamics in patients with metastatic melanoma:DNA damage and activity of re-pair enzymes 6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 2005;11:3402-9.
25. Olive PL, Chan APS, Cu CS. Comparison between the DNA precipitation and alkali unwinding assays for detecting DNA strand breaks and cross-links. Cancer Res1988;48:6444-9.
26. 6-alkylgua-nine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarba-zine and fotemustine. Cancer Res1991;51:619-23.
27. Kummar S, Kinders R, Gutierrez M, et al. Inhibition of poly (ADP-ribose) polymerase (PARP) byABT-888 in patients with advanced malignancies:results of a phase 0 trial. J Clin Oncol 2007;25:3518.
28. 6-benzylgua-nine followed bycarmustinein patients with advanced cancer. Clin Cancer Res 2000;6:3025-31.
29. 6- benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res 2005;11:7861-5.
30. 6-alkylguanine-DNA-alkyltransferase:phase I safety, pharmacody-namic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2006;12:1577-84.
31. Brada M, Judson I, Beale P, et al. Phase I dose-escalation and pharmacokinetic study of temozo-lomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999;81:1022-30.
32. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
33. Quinn JA, Pluda J, Dolan ME, et al. Phase II trial of carmustineplus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002;20:2277-83.
34. 6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemo-ther Pharmacol 2006;58:634-9.
35. Ranson M, Hersey P,Thompson D, et al. Arando-mised trial of the combination of lomeguatrib and temozolomide alone in patients with advanced mela-noma.JClinOncol2007;25:2540-5.
36. Staibano S, Pepe S, Lo Muzio L, et al. Poly(adeno-sine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 2005;36:724-31.
37. Wharton SB, McNelis U, Bell HS, Whittle IR. Expres-sion of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a gli-oma multicellular tumour spheroid model. Neuropa-thol Appl Neurobiol 2000;26:528-35.
38. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:1878-85.
39. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006;24:4731-7.
40. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94:1091-9.
41. Newlands ES, Stevens MFG, Wedge SR, Wheel-house RT, Brock C. Temozolomide:a review of its discovery, chemical properties, pre-clinical development and clinical trials. CancerTreat Rev1997;23:35-61.
42. Plummer ER, Lorigan P, Evans J, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol 2006;24:456s.
43. Fong P, SpicerJ, Reade S, et al. Phase I pharmaco-kinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of polyADP-ribose poly-merase (PARP), KU-0059436 (Ku) in patients (p)with advanced tumours. J Clin Oncol 2006;24:3022.
44. Pacher P, Liaudet L, MableyJG, Cziraki A, Hasko G, Szabo C. Beneficial effects of a novel ultrapotent pol-y(ADP-ribose) polymerase inhibitor in murine models of heart failure. IntJ Mol Med 2006;17:369-75.
45. Nakajima H, Kakui N, Ohkuma K, Ishikawa M, Hasegawa T. Anewly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tet- rahydrothiopyrano[4,3-d]-pyrimidine-4-one]:pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J Pharmacol Exp Ther 2005;312:472-81.
46. Woon EC,Threadgill MD. Poly(ADP-ribose)poly-merase inhibition-where now? Curr Med Chem 2005;12:2373-92.